TVGNW
Tevogen Bio Holdings Inc.
Price Chart
Latest Quote
$0.05
+0.00 (+2.04%)
Current Price
| Previous Close | $0.05 |
| Open | $0.04 |
| Day High | $0.06 |
| Day Low | $0.04 |
| Volume | 281,334 |
Stock Information
| Total Debt | $9.47M |
| Cash Equivalents | $692K |
| Net Income | $-21.94M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-21.94M |
| Book/sh | $-4.47 |
| Employees | 18 |
Financial Ratios
| Quick Ratio | 0.12 |
| Current Ratio | 0.29 |
Returns & Margins
| ROA | -294.43% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | -0.01 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| RSI | nan |
| ATR | nan |
| Shares Float | 1.07M |
| Volatility | 0.16 |
| Rel Volume | 20.00 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| YTD | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $nan | 281,334 |
| 2026-06-12 | $0.03 | 0 |
| 2026-06-11 | $0.03 | 0 |
| 2026-06-10 | $0.03 | 0 |
| 2026-06-09 | $0.03 | 0 |
| 2026-06-08 | $0.03 | 0 |
| 2026-06-05 | $0.03 | 0 |
| 2026-06-04 | $0.03 | 0 |
| 2026-06-03 | $0.03 | 0 |
| 2026-06-02 | $0.03 | 0 |
| 2026-06-01 | $0.03 | 0 |
| 2026-05-29 | $0.03 | 0 |
| 2026-05-28 | $0.03 | 0 |
| 2026-05-27 | $0.03 | 0 |
| 2026-05-26 | $0.03 | 0 |
| 2026-05-22 | $0.03 | 0 |
| 2026-05-21 | $0.03 | 0 |
| 2026-05-20 | $0.03 | 0 |
| 2026-05-19 | $0.03 | 0 |
| 2026-05-18 | $0.03 | 0 |
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $195,618 | $184,037 | $1,206,352 | $0 |
| Total Expenses | $26,140,515 | $53,564,488 | $8,843,025 | $953,083 |
| Other Income Expense | $60,701 | $40,021,145 | $-50,428,303 | $5,361,444 |
| Net Non Operating Interest Income Expense | $-195,618 | $-184,037 | $-1,206,352 | $0 |
| Interest Expense Non Operating | $195,618 | $184,037 | $1,206,352 | $0 |
| Operating Expense | $26,140,515 | $53,564,488 | $8,843,025 | $953,083 |
| General And Administrative Expense | $15,028,929 | $22,531,212 | $4,439,499 | $953,083 |
| Other Non Operating Income Expenses | - | $48,468,678 | $-50,428,303 | $-7,384,918 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,275,432 | $-13,727,380 | $-60,477,680 | $4,408,361 |
| Net Interest Income | $-195,618 | $-184,037 | $-1,206,352 | $0 |
| Normalized Income | $-26,336,133 | $-5,279,847 | $-60,477,680 | $172,820 |
| Net Income From Continuing And Discontinued Operation | $-26,275,432 | $-13,727,380 | $-60,477,680 | $4,408,361 |
| Total Operating Income As Reported | $-26,140,515 | $-53,564,488 | $-8,843,025 | $-13,724,064 |
| Net Income Common Stockholders | $-26,275,432 | $-13,727,380 | $-60,477,680 | $4,408,361 |
| Net Income | $-26,275,432 | $-13,727,380 | $-60,477,680 | $4,408,361 |
| Net Income Including Noncontrolling Interests | $-26,275,432 | $-13,727,380 | $-60,477,680 | $4,408,361 |
| Net Income Continuous Operations | $-26,275,432 | $-13,727,380 | $-60,477,680 | $4,408,361 |
| Pretax Income | $-26,275,432 | $-13,727,380 | $-60,477,680 | $4,408,361 |
| Special Income Charges | $0 | $-7,499,353 | $0 | $0 |
| Operating Income | $-26,140,515 | $-53,564,488 | $-8,843,025 | $-953,083 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $1,125,903 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-25,631,318 | $-4,692,229 | $-58,892,971 | $-953,083 |
| Total Unusual Items | $60,701 | $-8,447,533 | $0 | $5,361,444 |
| Total Unusual Items Excluding Goodwill | $60,701 | $-8,447,533 | $0 | $5,361,444 |
| Reconciled Depreciation | $509,197 | $403,581 | $378,357 | $230,823 |
| EBITDA (Bullshit earnings) | $-25,570,617 | $-13,139,762 | $-58,892,971 | $4,408,361 |
| EBIT | $-26,079,814 | $-13,543,343 | $-59,271,328 | $4,408,361 |
| Diluted NI Availto Com Stockholders | $-26,275,432 | $-13,727,380 | $-60,477,680 | $4,408,361 |
| Restructuring And Mergern Acquisition | $0 | $7,499,353 | $0 | - |
| Gain On Sale Of Security | $60,701 | $-948,180 | $2,712,676 | $5,361,444 |
| Research And Development | $11,111,586 | $31,033,276 | $4,403,526 | $5,774,298 |
| Selling General And Administration | $15,028,929 | $22,531,212 | $4,439,499 | $953,083 |
| Other Gand A | $4,151,279 | $7,053,876 | $3,344,031 | $953,083 |
| Salaries And Wages | $10,877,650 | $15,477,336 | $1,095,468 | $5,801,243 |
| Write Off | - | - | $250,000 | $0 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-8,234,726 | $-6,674,005 | $-94,428,897 | $342,080,652 |
| Total Assets | $4,382,994 | $3,461,675 | $5,505,503 | $357,138,356 |
| Total Non Current Assets | $2,843,211 | $1,100,773 | $3,782,524 | $356,864,000 |
| Other Non Current Assets | $1,065,884 | $575,841 | $271,141 | $356,864,000 |
| Non Current Deferred Assets | $183,546 | $0 | $2,582,870 | - |
| Current Assets | $1,539,783 | $2,360,902 | $1,722,979 | $274,356 |
| Other Current Assets | $828,592 | $919,088 | $670,582 | $145,170 |
| Receivables | $158,819 | $158,819 | $0 | $0 |
| Cash Cash Equivalents And Short Term Investments | $552,372 | $1,282,995 | $1,052,397 | $129,186 |
| Cash And Cash Equivalents | $552,372 | $1,282,995 | $1,052,397 | $129,186 |
| Cash Financial | $552,372 | $1,282,995 | $1,052,397 | $129,186 |
| Debt | ||||
| Net Debt | $5,498,628 | $1,368,005 | $93,879,603 | $33,812,735 |
| Total Debt | $7,501,490 | $2,885,859 | $95,419,572 | $40,007,933 |
| Long Term Debt And Capital Lease Obligation | $5,522,750 | $1,005,796 | $14,454,858 | $39,729,726 |
| Long Term Debt | $4,400,000 | $1,000,000 | $14,220,000 | $39,297,000 |
| Current Debt And Capital Lease Obligation | $1,978,740 | $1,880,063 | $80,964,714 | $278,207 |
| Current Debt | $1,651,000 | $1,651,000 | $80,712,000 | - |
| Other Current Borrowings | - | - | $80,712,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,617,720 | $10,135,680 | $99,934,400 | $15,057,704 |
| Total Non Current Liabilities Net Minority Interest | $5,549,229 | $1,092,976 | $14,454,858 | $14,707,250 |
| Derivative Product Liabilities | $26,479 | $87,180 | $0 | $7,250 |
| Current Liabilities | $7,068,491 | $9,042,704 | $85,479,542 | $350,454 |
| Other Current Liabilities | $331,086 | $403,233 | $120,149 | $237,600 |
| Current Notes Payable | $1,651,000 | $1,651,000 | $0 | - |
| Payables And Accrued Expenses | $4,758,665 | $6,759,408 | $4,394,679 | $350,454 |
| Payables | $3,590,127 | $5,450,245 | $3,418,378 | $350,454 |
| Accounts Payable | $3,340,127 | $5,200,245 | $3,418,378 | $210,454 |
| Non Current Deferred Liabilities | - | - | $14,700,000 | $14,700,000 |
| Equity | ||||
| Common Stock Equity | $-17,034,716 | $-15,473,995 | $-94,428,897 | $342,080,652 |
| Preferred Stock Equity | $8,799,990 | $8,799,990 | - | - |
| Total Equity Gross Minority Interest | $-8,234,726 | $-6,674,005 | $-94,428,897 | $342,080,652 |
| Stockholders Equity | $-8,234,726 | $-6,674,005 | $-94,428,897 | $342,080,652 |
| Retained Earnings | $-139,660,549 | $-113,385,117 | $-99,657,737 | $-14,784,691 |
| Other | ||||
| Ordinary Shares Number | $4,020,746 | $3,559,827 | $3,308,421 | $3,162,274 |
| Share Issued | $4,020,746 | $3,559,827 | $3,308,421 | $3,162,274 |
| Tangible Book Value | $-17,034,716 | $-15,473,995 | $-94,428,897 | $342,080,652 |
| Invested Capital | $-10,983,716 | $-12,822,995 | $503,103 | $342,080,652 |
| Working Capital | $-5,528,708 | $-6,681,802 | $-83,756,563 | $-76,098 |
| Capital Lease Obligations | $1,450,490 | $234,859 | $487,572 | $710,933 |
| Total Capitalization | $-3,834,726 | $-5,674,005 | $-80,208,897 | $342,080,652 |
| Additional Paid In Capital | $122,625,431 | $97,910,766 | $5,216,840 | $5,166,960 |
| Capital Stock | $8,800,392 | $8,800,346 | $12,000 | $356,865,343 |
| Common Stock | $402 | $356 | $12,000 | $356,865,343 |
| Preferred Stock | $8,799,990 | $8,799,990 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,122,750 | $5,796 | $234,858 | $432,726 |
| Current Capital Lease Obligation | $327,740 | $229,063 | $252,714 | $278,207 |
| Current Accrued Expenses | $1,168,538 | $1,309,163 | $976,301 | $578,769 |
| Dueto Related Parties Current | $250,000 | $250,000 | $0 | $140,000 |
| Net PPE | $1,593,781 | $524,932 | $928,513 | $1,306,870 |
| Accumulated Depreciation | $-414,529 | $-425,327 | $-263,118 | $-99,818 |
| Gross PPE | $2,008,310 | $950,259 | $1,191,631 | $1,406,688 |
| Leases | $126,285 | $263,217 | $263,217 | $263,217 |
| Other Properties | $1,423,473 | $228,490 | $469,862 | $684,919 |
| Machinery Furniture Equipment | $458,552 | $458,552 | $458,552 | $458,552 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $158,819 | $158,819 | $0 | $0 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,393,016 | $-11,998,730 | $-8,304,118 | $-215,395 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,328,577 | $-11,998,730 | $-8,171,118 | $-215,395 |
| Cash Flow From Continuing Operating Activities | $-12,328,577 | $-11,998,730 | $-8,171,118 | $-215,395 |
| Operating Gains Losses | $-60,701 | $58,180 | $21,750 | $-413,250 |
| Investing Activities | ||||
| Capital Expenditure | $-64,439 | - | $-133,000 | $-479,042 |
| Investing Cash Flow | $-64,439 | $0 | $-133,000 | $0 |
| Cash Flow From Continuing Investing Activities | $-64,439 | $0 | $-133,000 | $0 |
| Net Other Investing Changes | - | - | $342,916,930 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $4,862,393 | $11,000,000 | $0 | - |
| Financing Cash Flow | $11,662,393 | $12,229,328 | $3,872,250 | $0 |
| Cash Flow From Continuing Financing Activities | $11,662,393 | $12,229,328 | $3,872,250 | $0 |
| Net Other Financing Charges | $3,400,000 | $229,328 | $-127,750 | - |
| Net Preferred Stock Issuance | $0 | $11,000,000 | $0 | - |
| Preferred Stock Issuance | $0 | $11,000,000 | $0 | - |
| Net Common Stock Issuance | $4,862,393 | $0 | $-342,984,430 | $0 |
| Common Stock Issuance | $4,862,393 | $0 | - | - |
| Repurchase Of Capital Stock | - | - | $-342,984,430 | $0 |
| Other | ||||
| Issuance Of Debt | $3,400,000 | $1,000,000 | $4,000,000 | $0 |
| End Cash Position | $552,372 | $1,282,995 | $1,052,397 | $129,186 |
| Beginning Cash Position | $1,282,995 | $1,052,397 | $5,484,265 | $344,581 |
| Changes In Cash | $-730,623 | $230,598 | $-4,431,868 | $-215,395 |
| Net Issuance Payments Of Debt | $3,400,000 | $1,000,000 | $4,000,000 | $0 |
| Net Long Term Debt Issuance | $3,400,000 | $1,000,000 | $4,000,000 | $0 |
| Long Term Debt Issuance | $3,400,000 | $1,000,000 | $4,000,000 | $0 |
| Net PPE Purchase And Sale | $-64,439 | $0 | $-133,000 | $-479,042 |
| Purchase Of PPE | $-64,439 | $0 | $-133,000 | $-479,042 |
| Change In Working Capital | $-2,724,502 | $-5,487 | $293,205 | $737,688 |
| Change In Other Current Liabilities | $-297,976 | $-252,713 | $-223,361 | $-114,368 |
| Change In Other Current Assets | $-490,043 | $-511,011 | $323,742 | $-252,235 |
| Change In Payables And Accrued Expense | $-2,038,321 | $1,004,242 | $510,429 | $291,079 |
| Change In Accrued Expense | $-74,203 | $-681,450 | $-603,832 | $568,695 |
| Change In Payable | $-1,964,118 | $1,685,692 | $1,114,261 | $291,079 |
| Change In Account Payable | $-1,964,118 | $1,685,692 | $1,114,261 | $171,079 |
| Change In Prepaid Assets | $101,838 | $-246,005 | $-317,605 | $446,609 |
| Stock Based Compensation | $16,222,861 | $40,764,136 | $0 | $4,578,732 |
| Depreciation Amortization Depletion | $509,197 | $403,581 | $378,357 | $230,823 |
| Depreciation And Amortization | $509,197 | $403,581 | $378,357 | $230,823 |
| Depreciation | $509,197 | $403,581 | $378,357 | $230,823 |
| Gain Loss On Investment Securities | $-60,701 | $58,180 | $21,750 | $-413,250 |
| Net Income From Continuing Operations | $-26,275,432 | $-13,727,380 | $-60,477,680 | $4,408,361 |
| Other Non Cash Items | - | $-39,491,760 | $51,635,000 | $8,318,000 |
| Common Stock Payments | - | - | $-342,984,430 | $0 |
| Net Short Term Debt Issuance | - | - | $1,323,500 | $0 |
| Short Term Debt Issuance | - | - | $1,323,500 | $0 |
| Change In Receivables | - | - | $-267,000 | $0 |
| Unrealized Gain Loss On Investment Securities | - | - | $-2,734,426 | $-4,948,194 |
| Asset Impairment Charge | - | - | $250,000 | - |
Fetched: 2026-06-16